Toleranzia AB announced that the company has entered into an agreement with the contract manufacturer Curia (Scotland) Limited ("Curia") for the final manufacturing and packaging of the pharmaceutical product TOL2. Under the agreement, Curia will produce a finished freeze-dried and packaged pharmaceutical product of GMP quality for Toleranzia's upcoming clinical studies in patients with myasthenia gravis. During the year, Toleranzia has developed a process for production of freeze-dried TOL2 with excellent properties regarding stability, storage capacity and handling, which is used in the company's ongoing GLP toxicology study of the drug candidate.

To produce a finished drug product in sufficient quantities and with a quality suitable to future clinical studies, collaboration with the contract manufacturer is initiated. The production will include approximately 3,000 packages of sterile, freeze-dries TOL2 of GMP quality. The product will be ready for distribution to clinical centers and subsequent administration of the drug candidate to patients in Toleranzia's upcoming studies in patients with the autoimmune disease myasthenia gravis; The choice of partner is based on an extensive evaluation of other companies in the same industry, where Curia is a leading, international, well-established contract manufacturer with expertise and extensive experience in the manufacturing method developed by Toleranzia.